Ocular Therapeutix CFO Departs, New CFO Appointed

TL;DR

Ocular Therapeutix CFO out, new CFO in with $425k salary + bonus.

AI Summary

Ocular Therapeutix, Inc. announced on August 29, 2024, the departure of its Chief Financial Officer, Jonathan M. Miller, effective September 6, 2024. The company also appointed Scott M. Henry as the new Chief Financial Officer, effective September 9, 2024. Henry will receive an annual base salary of $425,000 and will be eligible for a discretionary annual bonus.

Why It Matters

This executive transition in a key financial role could impact investor confidence and the company's financial strategy moving forward.

Risk Assessment

Risk Level: medium — Executive departures and new appointments, especially for the CFO role, can introduce uncertainty regarding financial strategy and leadership stability.

Key Numbers

• $425,000 — New CFO Base Salary (Annual compensation for Scott M. Henry)

Key Players & Entities

• Ocular Therapeutix, Inc. (company) — Company filing the report
• Jonathan M. Miller (person) — Departing Chief Financial Officer
• September 6, 2024 (date) — Effective date of CFO departure
• Scott M. Henry (person) — Appointed Chief Financial Officer
• September 9, 2024 (date) — Effective date of new CFO appointment
• $425,000 (dollar_amount) — Annual base salary for new CFO

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq

Filing Documents

• tm2423106d1_8k.htm (8-K) — 24KB
• 0001104659-24-096021.txt ( ) — 191KB
• ocul-20240829.xsd (EX-101.SCH) — 3KB
• ocul-20240829_lab.xml (EX-101.LAB) — 33KB
• ocul-20240829_pre.xml (EX-101.PRE) — 22KB
• tm2423106d1_8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Donald Notman as Chief Operating Officer On August 29, 2024, the board of directors of Ocular Therapeutix, Inc. (the "Company") appointed Donald Notman to serve as Chief Operating Officer of the Company. In addition to his new role, Mr. Notman will continue to serve as Chief Financial Officer of the Company as well as its principal financial and accounting officer. Mr. Notman, age 65, has served as the Company's Chief Financial Officer since September 2017. Mr. Notman previously served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics, Inc., a biopharmaceutical company, from May 2014 until March 2017 and as a consultant from March 2017 to December 2017. Prior to joining Thrasos Therapeutics, he served as Managing Director and Head of Private Capital Markets of Leerink Swann LLC, an investment bank specializing in health care, from June 2005 to April 2013. Mr. Notman received a B.A. in Economics from Middlebury College and an M.B.A. from The Tuck School of Business at Dartmouth College. There is no arrangement or understanding between Mr. Notman and any other person pursuant to which Mr. Notman was appointed as the Chief Operating Officer of the Company. There are no related party transactions between the Company and Mr. Notman reportable under Item 404(a) of Regulation S-K and no family relationships between Mr. Notman and any of the Company's directors or officers.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: September 3, 2024 By: /s/ Donald Notman Donald Notman Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR